In The News
Personalized cancer vaccines offer hope for a cure
For more than 20 years, Hoag Cancer Institute has been a pioneer in vaccine research and is one of only a few medical centers in the world to utilize a patient’s own tumor cells to develop personalized melanoma vaccines. Cancer survivor Linda Rieser has become a self-proclaimed “poster-child” for the potential life-saving impact of … Read More
Dr. Craig Cox explains what superficial radiation therapy for skin lesions is and who is a candidate.
Superficial radiation is a non-invasive radiation therapy option for certain individuals with skin cancers or benign conditions. As opposed to other traditional methods of skin cancer treatment, which include surgically removing the cancerous/ benign area, superficial radiation treatment is administered through low-energy X-ray technology. This treatment type is optimal for lesions on the face, since … Read More
Prostate cancer: when should men be tested?
American nurses Credentialing Center’s (AnCC) Magnet recognition Program® has once again designated Hoag Hospital Newport Beach as a Magnet hospital. This designation has also been extended to Hoag Hospital Irvine since the commitment to nursing excellence is maintained at both hospitals. The ANCC Magnet Recognition Program® was developed to recognize health care organizations that provide … Read More
Study Shows Patient-Specific Vaccines for Metastatic Melanoma May Induce Durable Complete Regression
?Monday, September 27, 2010 Newport Beach, Calif. – Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated … Read More
Patient-Specific Cancer Immune Cell Therapy for Brain Tumors Promising as Adjunctive Therapy
Sunday, March 01, 2009 Newport Beach, Calif. – Hoag Hospital announced encouraging clinical study results for the instillation of a patient-specific cancer immune cell therapy as an adjunctive treatment for glioblastoma multiforme (GBM). The non-randomized, phase 2 study concluded that intralesional therapy with autologous lymphokine-activated killer (LAK) cells is safe and the survival sufficiently encouraging … Read More